Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation

SALT LAKE CITY, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from a large...
February 06, 2018 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results

Total Revenues of $194.0 Million GAAP Diluted EPS of $0.45 and Adjusted EPS of $0.31 Up 19 PercentCompany Raises Financial Guidance for Fiscal Year 2018 SALT LAKE CITY, Feb. 06,...
January 25, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018

SALT LAKE CITY, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2018 sales and earnings conference call with...
January 22, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer

SALT LAKE CITY, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the company is applauding a...
January 12, 2018 11:16 ET | Source: Myriad Genetics, Inc.

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer

SALT LAKE CITY, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug...
January 03, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca

SALT LAKE CITY, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that AstraZeneca will use the...
December 19, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president...
December 12, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Myriad’s BRACAnalysis CDx® Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfizer's PARP Inhibitor, Talazoparib

SALT LAKE CITY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that data from the EMBRACA trial...
December 08, 2017 18:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer Symposium

SALT LAKE CITY, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with...
December 06, 2017 18:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium

SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from a ground-breaking...